Artrya Limited · ASX:AYA
Artrya — Shareholder Meeting (November 2026)
25 slides from Artrya's shareholder meeting presentation, Nov 13, 2026
Slide 1: 2026 Chair and CEO Annual General Meeting Address and Presentation
Coronary Artery Disease. We see you. 2026 Chair and CEO Annual General Meeting Address and Presentation For personal use only PERTH, Australia, 13 November 2026: Artrya Limited (ASX: AYA) (Artrya or the Company), a medical technology company commercialising its Salix® AI-powered cloud platform, for
Slide 2: Chair's Address to the 2026 Annual General Meeting
Coronary Artery Disease. We see you. Chair's Address to the 2026 Annual General Meeting Good morning/afternoon, ladies and gentlemen and thank you for joining us today, whether that be in person or For personal use only virtually. Welcome to Artrya’s Annual General Meeting for the 2026 financial yea
Slide 3: Chair's Address: customers, leadership and priorities
The strategy with our foundation customers is to have them fully integrated and using the Salix Coronary Anatomy platform, Salix Coronary Plaque assessment and Salix Coronary Flow, once it is cleared by the FDA. We are fortunate that all three are Category 1 codes and largely covered by the insurers
Slide 4: Closing remarks from the Chairman
We look forward to the next 12 months with a lot of optimism and excitement Thank you. For personal use only Bernie Ridgeway, Chairman 13 November 2026 Artrya Limited I ACN 624 005 741 I 1257 Hay Street, West Perth Western Australia 6005 AUSTRALIA www.artrya.com 3
Slide 5: CEO Presentation: Scaling the Future of Heart Care
(ASX: AYA) or personal use only CEO Presentation 2026 Annual General Meeting 11:30am AWST (2:30pm AEDT) Friday, 13 November 2026 Scaling the Future of Heart Care John Konstantopoulos, CEO & Co-Founder ARTRYA FY2026 ANNUAL GENERAL MEETING
Slide 6: Important Notice
Important Notice IMPORTANT NOTICE AND DISCLAIMER These presentation materials have been prepared by Artrya Limited (Artrya or Company). By receiving the Presentation The Presentation Materials contain summary information about the Company and its activities which is current as at the date Materials,
Slide 7: Our purpose is to save lives through faster detection
or personal use only Our Purpose is to save lives through faster and more accurate detection of coronary artery disease 3 ARTRYA FY2026 ANNUAL GENERAL MEETING
Slide 8: Artrya – AI technology platform for coronary artery disease
Artrya – AI technology platform for coronary artery disease Salix® is the only real-time, point of care platform globally improving patient care and streamlining workflow or personal use only 1 Global health issue Heart disease kills more people than all cancers combined2 – a U.S. heart attack every
Slide 9: 2026: Building the base
or personal use only 2026: Building the base Focus on increasing utilisation and signing new health systems 5 ARTRYA FY2026 ANNUAL GENERAL MEETING
Slide 10: HonorHealth becomes first inbound commercial customer
HonorHealth becomes first inbound commercial customer Significant new health system customer from Arizona signs commercial agreement or personal use only Agreement Term TOP 100 U.S. HEALTH SYSTEM Five years Major commercial opportunity for Artrya Minimum value ~5 million people US$0.5m1 Served acros
Slide 11: Multiple achievements that support commercial growth
Multiple achievements that support commercial growth Successfully executed our commercial launch with five customers in the last 12 months – delivering growing revenues or personal use only Five U.S. customers secured SAPPHIRE Study launched Tanner Health, Cone Health (Kaiser Hospital), Northeast 6
Slide 12: Building our Resources and Leadership
Building our Resources and Leadership Strong balance sheet and growing strength of senior leadership or personal use only Cash1 Leadership and Governance Strengthened $67.2m 1 Commencement of Clayton Hatch as CFO • Clayton Hatch commenced as Artrya’s new CFO during the Quarter strengthening the mana
Slide 13: Existing U.S. commercial customers
Existing U.S. commercial customers Successful deployment of Salix® in the first U.S. hospital systems or personal use only • Non-profit health system serving communities across 5 hospitals fully integrated west Georgia and east Alabama • Network spanning 5 hospitals, 5 cardiovascular centres, Scan
Slide 14: Our customers continue to suffer major resourcing challenges
Our customers continue to suffer major resourcing challenges CT-first adoption has shifted the bottleneck downstream to reporting and analysis or personal use only 4-8 week backlogs CAD is deadly and common CCTA is the front-line test One scan, many insights Capacity cannot keep pace 1 in 3 deaths a
Slide 15: Salix: The Operating Platform for Cardiac CT
Salix®: The Operating Platform for Cardiac CT One reporting platform delivering real-time clinical, operational and financial value or personal use only More Clinical Capacity 50% faster reporting already seen enables more patients with existing resources, while reducing physician workload and repor
Slide 16: Salix is a single platform able to transform clinical workflows
Salix® is a single platform able to transform clinical workflows Salix® is a single solution that fits directly into the existing clinical workflow, no portals, no off-site vendors or personal use only Onsite - Manual CCTA Assessment Offsite - ‘Human in the loop’ Currently Current • Inefficient CCTA
Slide 17: Commercial footprint to support leading health systems
Commercial footprint to support leading health systems Foundation customers, SAPPHIRE sites, and our Atlanta support pod working together to drive U.S. growth or personal use only 1 MASS. GENERAL BRIGHAM 5 HCA HEALTHCARE 7 CONE HEALTH Massachusetts HQ: Nashville North Carolina 12 hospitals - Across
Slide 18: Flagship Novel Plaque Study - SAPPHIRE underway
Flagship Novel Plaque Study - SAPPHIRE underway Validating the novel Salix® Plaque Dispersion Score to identify patients at risk of heart attack or personal use only Overview Key phases Key benefits • Evaluate Salix® Plaque Dispersion Score assessing cardiovascular risk PHASE 1 1 Predict future adve
Slide 19: Commercial execution: A clear path forward
or personal use only Commercial execution A clear path forward 15 ARTRYA FY2026 ANNUAL GENERAL MEETING
Slide 20: Growing our Customers and Revenue base
Growing our Customers and Revenue base Plaque scan volumes are trending upward as early customers integrate and adopt Salix® or personal use only Salix® Coronary Plaque scan volumes Levers to grow revenue Quarterly, directional 01 Onboard all contracted customers and ‘Go Live’ Onboarding capabilitie
Slide 21: Salix Coronary Flow: expanding clinical utility
Salix® Coronary Flow: expanding clinical utility One scan, one platform – with access to U.S. reimbursement once FDA cleared or personal use only Salix® Anatomy Salix® Plaque Salix® Flow One scan FDA cleared + FDA cleared + Preparing additional clinical evidence* = complete coronary assessment Salix
Slide 22: Our pathway to creating future value for shareholders
Our pathway to creating future value for shareholders Our pathway to creating future value for shareholders Clearly identified value inflection points that drive towards repeatable adoption and a scaled Salix® platform or personal use only Scaled platform Widespread adoption, Commercial execution wi
Slide 23: Roadmap: Key priorities
Roadmap: Key priorities Converting contracted customers into recurring, expanding U.S. revenue or personal use only Complete deployment Grow plaque usage Build customer base - Secure Salix® Coronary Build clinical credibility across existing customers - building revenue per site SAPPHIRE partners &
Slide 24: Conclusion: Growth stage business with a strong moat
Conclusion: Growth stage business with a strong moat Artrya’s competitive advantage is built across four reinforcing layers — each harder to replicate and strengthening with scale or personal use only 1 One Integrated Platform 2 Real-Time, Point-of-Care Delivery ~8-10 minute automated analysis deliv
Slide 25: Thank you
or personal use only Thank you Corporate Enquiries Investor & Media Enquiries John Konstantopoulos David Allen or John Granger Co-Founder and Chief Executive Officer Hawkesbury Partners Tel: +61 8 6478 7816 Tel: +61 499 100 038 or +61 410 577 155 Email: contact@artrya.com Email: investors@artrya.com